"Carboplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An organoplatinum compound that possesses antineoplastic activity.
Concept/Terms
Carboplatin- Carboplatin
- cis-Diammine(cyclobutanedicarboxylato)platinum II
- CBDCA
Ribocarbo- Ribocarbo
- ribosepharm Brand of Carboplatin
Nealorin- Nealorin
- Prasfarma Brand of Carboplatin
Neocarbo- Neocarbo
- Neocorp Brand of Carboplatin
Paraplatin- Paraplatin
- Carboplat
- Paraplatine
- Bristol-Myers Squibb Brand of Carboplatin
Carbosin- Carbosin
- Pharmachemie Brand of Carboplatin
Carbotec- Carbotec
- Columbia Brand of Carboplatin
Ercar- Ercar
- Almirall Brand of Carboplatin
Platinwas- Platinwas
- Chiesi Brand of Carboplatin
Below are MeSH descriptors whose meaning is more general than "Carboplatin".
Below are MeSH descriptors whose meaning is more specific than "Carboplatin".
This graph shows the total number of publications written about "Carboplatin" by people in Harvard Catalyst Profiles by year, and whether "Carboplatin" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 3 | 4 | 7 |
| 1994 | 1 | 6 | 7 |
| 1995 | 3 | 6 | 9 |
| 1996 | 1 | 5 | 6 |
| 1997 | 1 | 6 | 7 |
| 1998 | 2 | 6 | 8 |
| 1999 | 3 | 5 | 8 |
| 2000 | 0 | 5 | 5 |
| 2001 | 3 | 8 | 11 |
| 2002 | 2 | 5 | 7 |
| 2003 | 0 | 11 | 11 |
| 2004 | 2 | 4 | 6 |
| 2005 | 4 | 15 | 19 |
| 2006 | 6 | 19 | 25 |
| 2007 | 4 | 3 | 7 |
| 2008 | 4 | 17 | 21 |
| 2009 | 4 | 13 | 17 |
| 2010 | 5 | 17 | 22 |
| 2011 | 4 | 22 | 26 |
| 2012 | 4 | 19 | 23 |
| 2013 | 2 | 13 | 15 |
| 2014 | 2 | 17 | 19 |
| 2015 | 8 | 13 | 21 |
| 2016 | 7 | 18 | 25 |
| 2017 | 5 | 7 | 12 |
| 2018 | 3 | 16 | 19 |
| 2019 | 4 | 17 | 21 |
| 2020 | 3 | 11 | 14 |
| 2021 | 2 | 12 | 14 |
| 2022 | 0 | 11 | 11 |
Below are the most recent publications written about "Carboplatin" by people in Profiles.
-
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors. Int J Clin Oncol. 2022 Dec; 27(12):1881-1890.
-
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer Discov. 2022 11 02; 12(11):2586-2605.
-
Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective. Pharmacoeconomics. 2022 12; 40(12):1247-1259.
-
First-line chemotherapy analysis on survival in carcinoma ovary patients: Data from a Northern Indian cancer center. J Cancer Res Ther. 2022 Oct-Dec; 18(6):1589-1596.
-
Combined-modality treatment for locally advanced cervical cancer in a woman with Bloom-like syndrome: A case report and review of the literature. Strahlenther Onkol. 2023 Jan; 199(1):102-105.
-
Mutational Footprint of Platinum Chemotherapy in a Secondary Thyroid Cancer. JCO Precis Oncol. 2022 08; 6:e2200183.
-
Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children's Oncology Group study. Neuro Oncol. 2022 06 01; 24(6):974-983.
-
Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma. Br J Haematol. 2022 07; 198(2):e32-e34.
-
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol. 2022 04; 33(4):384-394.
-
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. J Clin Oncol. 2022 04 20; 40(12):1323-1334.